Chemotherapy of Leishmaniasis: A Veterinary Perspective

Corral‐Caridad, María Jesús; Alunda, José María

doi:10.1002/9783527670383.ch2

Cited by 6 publications

(7 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…France, Spain) deserve deeper study. Antimonials have been, and still are in most regions, the standard etiological treatment of CanL despite the conflicting reports on the toxicity of Sb V [ 16 , 17 , 38 , 39 ], incomplete knowledge of its mechanism of action (MoA) [ 40 ] and reports on the emergence of resistance phenomena in some canine isolates of L. infantum [ 41 ]. Over 50% of all publications on the chemotherapy of CanL in the period dealt with the combination of Sb V with allopurinol.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the caveat against the medication of dogs with AmB seems reasonable when no new drugs are foreseen. No available drug or drug combination against CanL produces the parasitological cure [ 17 ], relapses are frequent, and the potential for development of resistant isolates of L. infantum is present [ 37 ]. Resistance of Leishmania to the currently used drugs has been widely reported [ 50 ], and there are indications of reduced sensitivity of L. infantum after repeated treatment with Sb V in both humans [ 51 ] and dogs [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Scientometric analysis of chemotherapy of canine leishmaniasis (2000–2020)

et al. 2021

View full text Add to dashboard Cite

Background Zoonotic visceral leishmaniasis by Leishmania infantum is a first-order pathology in canine veterinary clinics in endemic areas. Moreover, canine infections are considered the main reservoir for human disease; despite their importance in the control of the disease within a One Health approach, no scientometric study has been published. Aims of the study included analyzing the impact of canine leishmaniasis (CanL) on the scientific literature, drugs or combinations used, trends in the period from 2000 to 2020 and efficacy criteria employed. Methods A Web of Science (WOS)-based analysis of publications on CanL and chemotherapy of the disease in the period 2000–2020 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups, drugs and combinations, and efficacy criteria. Results Reports on CanL (n = 3324) represented < 16% of all publications on leishmaniasis (n = 20,968), and of these around 18% (n = 596) were related to chemotherapy. Publication records on CanL followed the distribution of the infection by L. infantum in endemic areas although Mediterranean countries were overrepresented in the reports on chemotherapy of CanL. Publications on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Pentavalent antimonials (SbV), alone or in combination with allopurinol, represented > 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs. Conclusions Chemotherapy of CanL still relies on SbV and combinations and to a lesser extent on miltefosine (MIL). Reports on chemotherapy are scarce and mostly publicly funded, and the variability of experimental conditions hampers the direct comparison of the efficacy of drugs, combinations and schedules. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the studies if intended for the practical management of the disease. Complete reports on the chemotherapy (etiological + symptomatic) would add value to the trials performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Scientometric analysis of chemotherapy of canine leishmaniasis (2000–2020)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…France, Spain) would deserve a deeper study. Antimonials have been, and still they are in most regions, the standard etiological treatment of CanL despite the con icting reports on toxicity of Sb V [16,17,38,39], the incomplete knowledge of its mechanism of action (MoA) [40] and reports on the emergence of resistance phenomena in some canine isolates of L.infantum [41]. Over 50% of all publications on chemotherapy of CanL in the period dealt with the combination of Sb V with allopurinol.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the caveat against the medication of dogs with AmB seems reasonable when no new drugs are foreseen. No available drug or combination against CanL causes the parasitological cure [17], relapses are frequent and the potential for development of resistant isolates of L. infantum is present [37]. Resistance of Leishmania to the currently used drugs has been widely reported [50] and there are indications of reduced sensitivity of L.infantum after repeated treatment with Sb V in both humans [51] and dogs [52].…”

Section: Discussionmentioning

confidence: 99%

Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020)

Olías-Molero

Fontán-Matilla

Cuquerella

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Zoonotic visceral leishmaniasis by Leishmania infantum is a first order pathology in veterinary clinics of dogs in endemic areas. Moreover, canine infections are considered the main reservoir for human disease; despite their importance in the control of the disease within a One Health approach no scientometric study has been published. Aims of the study included the impact of canine leishmaniasis (CanL) on scientific literature, drugs or combinations used, trends in the period from 2000-2020 and efficacy criteria employed. Methods: A Web of Science (WOS) based analysis of publications on CanL and chemotherapy of the disease in the period 2000-2020 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups, drugs and combinations, and efficacy criteria. Results: Reports on CanL (n=3,324) represented less than 16% of all publications on leishmaniasis (n=20,968) and from these around 18% (n=596) were related to chemotherapy. Publication records on CanL followed the distribution of the infection by L.infantum in endemic areas although Mediterranean countries were overrepresented in the reports on chemotherapy of CanL. Publications on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Pentavalent antimonials (Sb V ), alone or in combination with allopurinol, represented over 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs. Conclusions: Chemotherapy of CanL still relies on Sb V and combinations and to a lesser extent on miltefosine (MIL). Reports on chemotherapy are scarce, mostly publicly funded and the variability of experimental conditions hampers the direct comparison of the efficacy of drugs, combinations and schedules. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the studies if intended for the practical management of the disease. Complete reports of the chemotherapy (etiological + symptomatic) would add value to the trials performed.

show abstract

“…and in 2010 there were no publications in 2010. Whether or not the comparatively easy induction of resistance in vitro [33] and reports on its lower e cacy [34] Antimonials have been, and still they are in many regions, the standard etiological treatment of CanL despite the con icting reports on toxicity of Sb V [16,17,36,37]; incomplete knowledge of its mechanism of action (MoA) [38] and resistance reports on the emergence of resistance phenomena in some canine isolates of L.infantum [39]. Over 50% of all publications on chemotherapy of CanL in the period deal with the combination of Sb V with allopurinol.…”

Section: Drugs Used: Trenched or Better?mentioning

confidence: 99%

Bibliometric Analysis of Chemotherapy of Canine Leishmaniasis (2000-2017)

Olías-Molero

Fontán-Matilla

Alunda

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background Zoonotic visceral leishmaniasis by Leishmania infantum is a first order pathology in veterinary clinics of dogs in endemic areas. Moreover, canine infections (CanL) are considered the main reservoir for human disease. Despite the importance of CanL in the control of the diseases within a One Health approach no scientometric study has been published. Aims of the study included the impact of CanL on scientific literature, drugs or combinations used, trends in the period from 2000-2017 and efficacy criteria employed. Methods A Web of Science (WOS) based analysis of publications on CanL and chemotherapy of the disease in the period 2000-2017 was carried out using a stepwise methodology. Data were analyzed by year, geographical origin, chemical groups and drugs and efficacy criteria. Results Reports on CanL represented a 20% of all publications on leishmaniasis and from these ca. 14% were related to chemotherapy. Publications records on CanL followed the distribution of the infection in endemic areas although an overrepresentation of Mediterranean countries was evident. Published reports on the main antileishmanial drugs used in clinical practice showed a sustained tendency in the period analyzed. Sb V , alone or in combination with allopurinol, represented over 50% of all publications on chemotherapy of CanL despite the availability of more recently marketed drugs. Conclusions Chemotherapy of CanL still relies on Sb V and combinations. Reports on chemotherapy are scarce, mostly publicly funded and the variability of experimental conditions make extraordinarily difficult the comparison of efficacy. The vast majority of reports on efficacy do not include any information on supportive therapy; this reduces the actual value of the experiments if intended for the practical management of the disease. Complete reports of the treatments (etiological + symptomatic) would add value to the assays performed.

show abstract

Chemotherapy of Leishmaniasis: A Veterinary Perspective

Cited by 6 publications

References 104 publications

Scientometric analysis of chemotherapy of canine leishmaniasis (2000–2020)

Scientometric analysis of chemotherapy of canine leishmaniasis (2000–2020)

Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020)

Bibliometric Analysis of Chemotherapy of Canine Leishmaniasis (2000-2017)

Contact Info

Product

Resources

About